BioXcel Therapeutics Net Worth
BioXcel Therapeutics Net Worth Breakdown | BTAI |
BioXcel Therapeutics Net Worth Analysis
BioXcel Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including BioXcel Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of BioXcel Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform BioXcel Therapeutics' net worth analysis. One common approach is to calculate BioXcel Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares BioXcel Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing BioXcel Therapeutics' net worth. This approach calculates the present value of BioXcel Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of BioXcel Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate BioXcel Therapeutics' net worth. This involves comparing BioXcel Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into BioXcel Therapeutics' net worth relative to its peers.
To determine if BioXcel Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BioXcel Therapeutics' net worth research are outlined below:
| BioXcel Therapeutics is way too risky over 90 days horizon | |
| BioXcel Therapeutics may become a speculative penny stock | |
| BioXcel Therapeutics appears to be risky and price may revert if volatility continues | |
| BioXcel Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.27 M. Net Loss for the year was (59.6 M) with loss before overhead, payroll, taxes, and interest of (225 K). | |
| BioXcel Therapeutics currently holds about 233.45 M in cash with (72.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| BioXcel Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board ... |
BioXcel Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in BioXcel Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BioXcel Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know BioXcel Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioXcel Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioXcel Therapeutics backward and forwards among themselves. BioXcel Therapeutics' institutional investor refers to the entity that pools money to purchase BioXcel Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 1.8 K | Bank Of America Corp | 2025-03-31 | 1.5 K | Group One Trading, Lp | 2025-03-31 | 1.3 K | Sbi Securities Co Ltd | 2025-03-31 | 851 | Federated Hermes Inc | 2025-03-31 | 237 | Allsquare Wealth Management Llc | 2025-03-31 | 175 | Washington Trust Advisors, Inc. | 2025-03-31 | 160 | Tower Research Capital Llc | 2025-03-31 | 152 | Jpmorgan Chase & Co | 2025-03-31 | 116 | Murchinson Ltd. | 2025-03-31 | 136.1 K | Ubs Group Ag | 2025-03-31 | 101.8 K |
Follow BioXcel Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.69 M.Evaluate BioXcel Therapeutics' management efficiency
BioXcel Therapeutics has return on total asset (ROA) of (0.5247) % which means that it has lost $0.5247 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.6694) %, meaning that it created substantial loss on money invested by shareholders. BioXcel Therapeutics' management efficiency ratios could be used to measure how well BioXcel Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The BioXcel Therapeutics' current Net Tangible Assets is estimated to increase to about 89.5 M, while Total Assets are projected to decrease to under 36.4 M.Evaluating the management effectiveness of BioXcel Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The BioXcel Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 46.7502 | Revenue | Quarterly Revenue Growth (0.71) | Revenue Per Share 0.568 | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioXcel Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioXcel Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioXcel Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioXcel Therapeutics time-series forecasting models is one of many BioXcel Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioXcel Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
BioXcel Therapeutics Earnings per Share Projection vs Actual
BioXcel Therapeutics Corporate Management
| Javier JD | Chief VP | Profile | |
| Frank Yocca | Chief Scientific Officer | Profile | |
| Mary Coleman | VP Relations | Profile | |
| Javier Rodriguez | Chief VP | Profile | |
| Cedric Burg | VP Management | Profile | |
| Robert Scala | Vice Planning | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.12) | Revenue Per Share 0.568 | Quarterly Revenue Growth (0.71) | Return On Assets (0.52) | Return On Equity |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.